Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript
Seeking Alpha8/6/2026Neutral
DNA
Ginkgo Bioworks HoldingsNYSEHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$457.24M
P/E Ratio
—
EPS
$-5.33
Beta
1.79
52W High
$17.58
52W Low
$5.37
50-Day MA
$8.61
200-Day MA
$8.59
Dividend Yield
—
Profit Margin
-219.60%
Forward P/E
—
PEG Ratio
—
About Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms suitable for a wide range of sectors, including pharmaceuticals, agriculture, and industrial biotechnology. The company's innovative platform streamlines cellular design and manufacturing, positioning Ginkgo as a key player in addressing critical global challenges such as climate change and food security. With a strong focus on sustainable biotechnology solutions, Ginkgo is well-equipped to tap into the increasing market demand for bio-based alternatives, highlighting its potential for significant growth and transformative impact across various industries.
Fundamentals
| Revenue (TTM) | $132.42M |
| Gross Profit (TTM) | $90.10M |
| EBITDA | $-261.72M |
| Operating Margin | -285.00% |
| Return on Equity | -59.90% |
| Return on Assets | -16.70% |
| Revenue/Share (TTM) | $2.26 |
| Book Value | $6.60 |
| Price-to-Book | 1.09 |
| Price-to-Sales (TTM) | 3.45 |
| EV/Revenue | 4.223 |
| EV/EBITDA | -1.79 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -48.50% |
| Shares Outstanding | $55.38M |
| Float | $49.87M |
| % Insiders | 4.43% |
| % Institutions | 73.31% |
Historical Volatility
HV 10-Day
69.93%
HV 20-Day
78.35%
HV 30-Day
77.84%
HV 60-Day
74.58%
HV Rank
26.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($7.00 target)
1
Buy1
Sell1
Strong SellLatest News
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identification BOSTON, May 26, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™ , a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific and Inductive Bio . ADME-One delivers a high-throughput Tier 1 ADME (absorption, distribution, metabolism, and excretion) panel paired with best-in-class AI-powered human pharmacokinetic (PK) projection and fully integrated compound management.
PRNewsWire5/26/2026Neutral
Ginkgo Bioworks: Another Lost Year
Ginkgo Bioworks (DNA) reported Q1 revenues of $19.5M, down nearly 50% year-over-year and badly missing street estimates even after Biosecurity adjustments. Management is pivoting to autonomous labs but refuses to provide revenue guidance, causing analyst estimates to fall further. DNA continues to burn significant cash, with Q1 cash burn at $49M and 2026 guidance of $125M–$150M, leaving $373M in cash and no debt but weakening flexibility.
Seeking Alpha5/13/2026Negative
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the first quarter of 2026 that ended March 31, 2026. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com.
PRNewsWire5/7/2026Neutral
Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation
Presentation and Q&A session scheduled for post-market on Thursday, May 7, 2026 BOSTON, April 30, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2026, on Thursday, May 7, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.
PRNewsWire4/30/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DNA and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026